Skip to main content

E. K. Charles, MBS

Authored Items

Defitelio (Defibrotide Sodium): FDA Approved for Patients with Hepatic Veno-Occlusive Disease
By E. K. Charles, MBS
TOP - May 2016, Vol 9, No 2
Drug Updates
This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT. Read More ›
IDH Mutations Have Clinically Significant Implications in Patients with Primary Myelofibrosis
By E. K. Charles, MBS
TOP - February 2016, Vol 9, No 1
Hematologic Cancers
IDH mutations have been observed among various groups of patients, including those with glioblastoma multiforme, grade 2 and 3 gliomas, and secondary glioblastomas, as well as patients with acute myeloid leukemia. However, limited data exist among patients with Philadelphia-negative myeloproliferative neoplasms. Read More ›
Early Intervention of Inflammation May Be Key in Myeloproliferative Neoplasms
By E. K. Charles, MBS
TOP - February 2016, Vol 9, No 1
Hematologic Cancers
With recent evidence pointing to a link between chronic inflammation and Philadelphia-negative myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, and myelofibrosis, Hans Carl Hasselbalch, MD, DMSc, and Mads Emil Bjorn, MD, PhDc, Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark, recently published a review article purporting that myeloproliferative neoplasms are inflammatory diseases. Read More ›